iBio reports fiscal 2026 results, cites progress across obesity antibody pipeline
iBio said it advanced its myostatin and Activin E antibody programs through fiscal year 2026 and ended the period with about $88 million in cash and investments.
iBio, Inc. reported financial results for the fiscal year ended June 30, 2026, alongside a corporate update on its pipeline of long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases.
The company said it advanced IBIO-600, its long-acting myostatin antibody, through the single ascending dose portion of its first-in-human Phase 1 trial, having dosed 31 of the 32 planned participants across all four planned cohorts, with no safety findings that prevented dose escalation.1 iBio said it is now preparing to advance IBIO-600 into the multiple ascending dose escalation portion of the clinical trial.1
For IBIO-610, its Activin E antibody, the company reported that in obese non-human primates, a single dose produced near-complete suppression of active Activin E for up to eight weeks and showed a prolonged pharmacokinetic profile supporting the potential for infrequent dosing.1 In rodent studies, the company said the program showed fat-selective weight loss, additive weight loss and enhanced body-composition effects when combined with semaglutide, along with prevention of weight regain after stopping GLP-1 treatment.1
iBio also said it advanced IBIO-800, its myostatin times Activin A bispecific antibody, into IND-enabling development after selecting a development candidate, and began CMC and IND-enabling nonclinical work, with an initial disease focus on pulmonary hypertension associated with heart failure with preserved ejection fraction.1 Separately, the company said it in-licensed all rights to AstralBio's amylin receptor antibody program, covering a portfolio of next-generation antibody agonists.1
On financing, iBio said it closed a public offering in August 2025 with potential gross proceeds of up to $100 million if all warrants are exercised, led by Balyasny Asset Management1, and closed a $26 million private placement in January 2026 led by Frazier Life Sciences.1 CFO Felipe Druan said the financings extended the company's cash runway into fiscal year 2028.1 As of June 30, 2026, iBio held cash and cash equivalents and investments in debt securities of approximately $88.0 million.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.